You have free access to this content

Cancer

Cover image for Vol. 117 Issue 24

15 December 2011

Volume 117, Issue 24

Pages 5433–5633

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Thanks to Authors and Peer Reviewers
    1. You have free access to this content
    2. You have free access to this content
      Dana-Farber seeks to reach young adult cancer patients (page 5434)

      Carrie Printz

      Version of Record online: 2 DEC 2011 | DOI: 10.1002/cncr.26704

    3. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Thanks to Authors and Peer Reviewers
    1. You have free access to this content
      Why Cancer matters (pages 5436–5438)

      Fadlo R. Khuri

      Version of Record online: 18 NOV 2011 | DOI: 10.1002/cncr.26691

      • original image

      This is Dr. Fadlo Khuri's introductory editorial as Editor-in-Chief of Cancer.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Thanks to Authors and Peer Reviewers
    1. You have free access to this content
      Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis (pages 5439–5449)

      Alfonso Quintás-Cardama, Nitin Jain and Srdan Verstovsek

      Version of Record online: 20 JUN 2011 | DOI: 10.1002/cncr.26256

      Systemic mastocytosis (SM) is a hematopoietic malignancy characterized by the excessive proliferation of neoplastic mast cells. The heterogeneity in the clinical course of patients with SM and recent advances in the genetic and immunophenotypic characterization of neoplastic mast cells may help to improve current diagnostic, taxonomic, and therapeutic approaches in SM.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Thanks to Authors and Peer Reviewers
    1. Disease Site

      Breast Disease
      You have free access to this content
      Was the drop in mammography rates in 2005 associated with the drop in hormone therapy use? (pages 5450–5460)

      Nancy Breen, Kathleen A. Cronin, Jasmin A. Tiro, Helen I. Meissner, Timothy S. McNeel, Susan A. Sabatino, Florence K. Tangka and Stephen H. Taplin

      Version of Record online: 22 AUG 2011 | DOI: 10.1002/cncr.26218

      • original image
      • original image
      • original image

      Multivariate logistic regression was used to test for an interaction between hormone therapy use and survey year controlling for a range of measurable factors in data from the 2000 and 2005 National Health Interview Surveys. The results indicate that the change in hormone therapy use was associated with the drop in mammography use for women ages 50 to 64 years but not for women aged ≥65 years.

    2. You have free access to this content
      Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer (pages 5461–5468)

      Heather L. McArthur, Kathleen M. Mahoney, Patrick G. Morris, Sujata Patil, Lindsay M. Jacks, Jane Howard, Larry Norton and Clifford A. Hudis

      Version of Record online: 16 JUN 2011 | DOI: 10.1002/cncr.26171

      • original image

      Although several large, randomized trials established the benefits of adjuvant trastuzumab with chemotherapy, the benefit for women with small, node-negative HER2-positive (HER2+) disease is unknown, as these patients were largely excluded from these trials. This retrospective, single-institution, sequential cohort study indicates that women with small, node-negative, HER2+ primary breast cancers likely derive significant benefit from adjuvant trastuzumab with chemotherapy.

    3. You have free access to this content
      Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms (pages 5469–5475)

      N. Lynn Henry, Mousumi Banerjee, Max Wicha, Catherine Van Poznak, Jeffrey B. Smerage, Anne F. Schott, Jennifer J. Griggs and Daniel F. Hayes

      Version of Record online: 20 JUN 2011 | DOI: 10.1002/cncr.26230

      • original image
      • original image

      Bothersome musculoskeletal symptoms affect about half of women with early stage breast cancer treated with aromatase inhibitors. In this pilot clinical trial, treatment with duloxetine appeared to significantly improve pain and functioning, and was relatively well tolerated.

    4. You have free access to this content
      Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome (pages 5476–5484)

      Yun Gong, Lei Huo, Ping Liu, Nour Sneige, Xiaoping Sun, Naoto T. Ueno, Anthony Lucci, Thomas A. Buchholz, Vicente Valero and Massimo Cristofanilli

      Version of Record online: 28 JUN 2011 | DOI: 10.1002/cncr.26179

      • original image
      • original image

      In this retrospective study, the authors examined enhancer of zeste homolog 2 (EZH2) expression in inflammatory breast cancer (IBC) tumors and evaluated the relation between EZH2 expression and patient survival. The results indicated that positive EZH2 status can be used to identify a subset of patients with IBC who have a relatively worse prognosis, and targeting EZH2 may provide a novel way to improve clinical outcome in patients with IBC.

    5. You have free access to this content
      Treatment adherence and outcome in women with inflammatory breast cancer : Does race matter? (pages 5485–5492)

      Fundagul Andic, Karen Godette, Ruth O'Regan, Amelia Zelnak, Tian Liu, Monica Rizzo, Sheryl Gabram and Mylin Torres

      Version of Record online: 20 JUN 2011 | DOI: 10.1002/cncr.26187

      • original image
      • original image
      • original image

      Being African American or Caucasian did not appear to impact treatment adherence in inflammatory breast cancer. However, African American patients tended to have poorer response to standard multimodality treatment and worse outcome than Caucasian patients.

    6. Gastrointestinal Disease
      You have free access to this content
      Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer (pages 5493–5499)

      Shaun McKenzie, Rebecca Nelson, Brian Mailey, Wendy Lee, Vincent Chung, Stephen Shibata, Julio Garcia-Aguilar and Joseph Kim

      Version of Record online: 20 JUN 2011 | DOI: 10.1002/cncr.26245

      • original image

      The role of adjuvant chemotherapy for patients with American Joint Committee on Cancer (AJCC) stage II colon cancer remains unclear. In an investigation based on data from the California Cancer Registry, the authors observed that patients with AJCC stage II colon cancer who received adjuvant chemotherapy had improved survival.

    7. Genitourinary Disease
      You have free access to this content
      Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC) : Results from a large multicenter collaborative study (pages 5500–5508)

      Maria Vassilakopoulou, Thibault de la Motte Rouge, Pierre Colin, Adil Ouzzane, David Khayat, Meletios-Athanasios Dimopoulos, Christos A. Papadimitriou, Aristotle Bamias, Géraldine Pignot, François Xavier Nouhaud, Sophie Hurel, Laurent Guy, Pierre Bigot, Mathieu Roumiguié, Morgan Rouprêt and for the French collaborative national database on UUT-UCC

      Version of Record online: 2 JUN 2011 | DOI: 10.1002/cncr.26172

      • original image

      Urothelial cell carcinoma of the upper urinary tract was a rare, aggressive urologic cancer with a propensity for multifocality, local recurrence, and metastasis. Adjuvant postoperative chemotherapy had a minimal effect on overall survival in these patients.

    8. You have free access to this content
      2′-5′ oligoadenylate synthetase 1 polymorphism is associated with prostate cancer (pages 5509–5518)

      Sanjay Mandal, Fisseha Abebe and Jaideep Chaudhary

      Version of Record online: 2 JUN 2011 | DOI: 10.1002/cncr.26219

      • original image
      • original image

      In this study, the authors investigated the association between the functional polymorphism reference single nucleotide polymorphism (rs) number rs2660 in 2′-5′ oligoadenylate synthetase 1 (OAS1) and prostate cancer. The results suggest that the rs2660 AA genotype is associated significantly with prostate cancer, whereas the GG genotype protects against prostate cancer.

    9. Gynecologic Oncology
      You have free access to this content
      Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin (pages 5519–5528)

      Francesca Casagrande, Emiliano Cocco, Stefania Bellone, Christine E. Richter, Marta Bellone, Paola Todeschini, Eric Siegel, Joyce Varughese, Dan Arin-Silasi, Masoud Azodi, Thomas J. Rutherford, Sergio Pecorelli, Peter E. Schwartz and Alessandro D. Santin

      Version of Record online: 20 JUN 2011 | DOI: 10.1002/cncr.26215

      • original image
      • original image
      • original image
      • original image

      Chemotherapy-resistant CD44+ ovarian cancer stem cells express claudin-4 (ie, the high-affinity Clostridium perfringens enterotoxin [CPE] receptor) at significantly higher levels when compared with matched autologous CD44 ovarian cancer cells and died minutes after exposure to CPE in vitro. Intraperitoneal administrations of CPE in SCID mice harboring established xenografts of chemotherapy-resistant CD44+ ovarian cancer stem cells had a significant inhibitory effect on tumor progression leading to the cure and/or long-term survival of all treated animals. CPE may represent an unconventional, potentially highly effective strategy to eradicate chemotherapy-resistant cancer stem cells.

    10. Hematologic Malignancies
      You have free access to this content
      Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome (pages 5529–5537)

      Jose Ramon Gonzalez-Porras, Iris Cordoba, Esperanza Such, Benet Nomdedeu, Teresa Vallespi, Felix Carbonell, Elisa Luño, Maite Ardanaz, Fernando Ramos, Carme Pedro, Valle Gomez, Raquel de Paz, Mercedes Sanchez-Barba, Guillermo F. Sanz, and Consuelo del Cañizo and on behalf of the Spanish Myelodysplastic Syndrome Registry

      Version of Record online: 2 JUN 2011 | DOI: 10.1002/cncr.26173

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Thrombocytopenia is very common in myelodysplastic syndrome and constitutes a relevant clinical problem in a significant fraction of these patients. Severe thrombocytopenia identifies a subgroup of very poor prognosis patients within the low/intermediate-1 International Prognostic Scoring System (IPSS) risk groups. These patients should be considered for treatment alternatives capable of altering the natural history of the disorder earlier than their IPSS score would indicate.

    11. Lung Disease
      You have free access to this content
      Survival after second primary lung cancer : A population-based study of 187 Hodgkin lymphoma patients (pages 5538–5547)

      Michael T. Milano, Huilin Li, Louis S. Constine and Lois B. Travis

      Version of Record online: 20 JUN 2011 | DOI: 10.1002/cncr.26257

      • original image
      • original image

      It is known that Hodgkin lymphoma (HL) survivors experience an increased risk of developing nonsmall cell lung cancer (NSCLC). In this study, compared with patients who had de novo NSCLC, HL survivors had a significant 1.3-fold to 1.7-fold reduction in survival after an NSCLC diagnosis.

    12. Neuro-Oncology
      You have free access to this content
      A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies (pages 5548–5559)

      Evan J. Wuthrick, Mitchell Kamrava, Walter J. Curran Jr, Maria Werner-Wasik, Kevin A. Camphausen, Terry Hyslop, Rita Axelrod, David W. Andrews, Jon Glass, Mitchell Machtay and Adam P. Dicker

      Version of Record online: 3 JUN 2011 | DOI: 10.1002/cncr.26216

      • original image
      • original image
      • original image

      A phase 1b study of concurrent sunitinib 37.5 mg and radiation therapy was performed in patients with primary and metastatic central nervous system malignancies. An acceptable toxicity and adverse event profile was observed with no grade 3-5 hypertensive events or intracerebral hemorrhages, and 6-month neurologic progression-free survival was 58%.

    13. Discipline

      Disparities Research
      You have free access to this content
      Use of human papillomavirus vaccines among young adult women in the United States: An analysis of the 2008 National Health Interview Survey (pages 5560–5568)

      Rebecca Anhang Price, Jasmin A. Tiro, Mona Saraiya, Helen Meissner and Nancy Breen

      Version of Record online: 5 JUL 2011 | DOI: 10.1002/cncr.26244

      • original image

      Human papillomavirus vaccine coverage among young adult women was low in 2008, and was lower among the uninsured than among the insured. Primary reasons for lack of interest in the vaccine were belief that it was not needed, not knowing enough about it, concerns about safety, and not being sexually active.

    14. You have free access to this content
      Hospital racial composition and the treatment of localized prostate cancer (pages 5569–5578)

      Craig Evan Pollack, Justin E. Bekelman, K. J. Liao and Katrina Armstrong

      Version of Record online: 20 JUN 2011 | DOI: 10.1002/cncr.26232

      Large racial differences exist in where black and white patients tend to receive care and in the treatment of localized prostate cancer. Regardless of race, men who receive care at hospitals with a high proportion of black patients were significantly less likely to receive active treatment for localized prostate cancer compared with men seen at hospitals with fewer black patients.

    15. Radiation Oncology
      You have free access to this content
      Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer : Long-term results of CALGB 99809 (pages 5579–5588)

      Mark D. Hurwitz, Susan Halabi, Laura Archer, Lamar S. McGinnis, Michael R. Kuettel, Steven J. DiBiase and Eric J. Small

      Version of Record online: 4 MAR 2011 | DOI: 10.1002/cncr.26203

      • original image
      • original image
      • original image
      • original image

      A Cancer and Leukemia Group B multicenter phase 2 trial was performed to assess toxicity and efficacy of combination of external beam radiation therapy and transperineal prostate brachytherapy boost with androgen deprivation therapy for intermediate-risk prostate cancer. With >6 years median follow-up, this therapeutic regimen resulted in excellent disease-free survival with acceptable toxicity.

    16. You have free access to this content
      Impact of race on biochemical disease recurrence after prostate brachytherapy (pages 5589–5600)

      Kosj Yamoah, Nelson Stone and Richard Stock

      Version of Record online: 20 JUN 2011 | DOI: 10.1002/cncr.26183

      • original image
      • original image
      • original image

      In this study, the influence of race on biochemical disease-free survival (BDFS) was examined among men who received prostate brachytherapy. African American race appeared to be an independent, negative predictor of BDFS after prostate brachytherapy and may highlight the need for more aggressive therapy in this patient population.

    17. Translational Research
      You have free access to this content
      Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2 (pages 5601–5611)

      Elizabeth A. Kuczynski, Alicia M. Viloria-Petit and Brenda L. Coomber

      Version of Record online: 20 JUN 2011 | DOI: 10.1002/cncr.26247

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The authors identified a significant negative relation between transforming growth factor beta levels in conditioned media from colorectal carcinoma cell lines and vascular endothelial growth factor receptor 2 (VEGFR2) levels in endothelial cells. This effect appeared to be ALK5-dependent, and in colorectal xenografts may account for heterogeneous VEGFR2 and phospho-Smad2 vessel phenotypes in combination with other microenvironmental factors.

    18. You have free access to this content
      Human papillomavirus vaccine uptake among 9- to 17-year-old girls : National Health Interview Survey, 2008 (pages 5612–5620)

      Charlene A. Wong, Zahava Berkowitz, Christina G. Dorell, Rebecca Anhang Price, Jennifer Lee and Mona Saraiya

      Version of Record online: 20 JUN 2011 | DOI: 10.1002/cncr.26246

      • original image

      Less than one quarter of girls 9-17 years old initiate human papillomavirus (HPV) vaccination. Efforts to increase HPV uptake should focus on vaccinating the target age group, encouraging providers to give parents vaccine information, and promoting access to reduced-cost vaccines and well-child check-ups.

  5. Thanks to Authors and Peer Reviewers

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Thanks to Authors and Peer Reviewers
    1. You have free access to this content

SEARCH

SEARCH BY CITATION